5 terminated. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 5 |
| Phase 2 | 4 | Terminated 4 |
Follow ALL: new trials by email Literature Review of ALL trials Research Report on ALL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL Cohort 1, GNR-084, Cohort 2, GNR-084, Cohort 3, GNR-084 - B-precursor Acute Lymphoblastic Leukemia, ALL | Phase 1 / Phase 2 | Terminated | AO GENERIUM | 14 | 2020-10-15 | 2026-09-21 |
| Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders T-allo10 - AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome) | Phase 1 | Terminated | Roncarolo, Maria Grazia, MD | 5 | 2017-08-30 | 2024-07-18 |
| Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia OTS167IV - AML, Advanced MDS | Phase 1 / Phase 2 | Terminated | OncoTherapy Science, Inc. | 32 | 2016-04-01 | 2021-11-24 |
| Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft Naive T-cell Depleted Stem Cell Transplant, Stem Cell Transplant No Manipulation, Isolex device from Baxter - ALL, ANLL | Phase 1 / Phase 2 | Terminated | Duke University | 15 | 2007-07-01 | 2013-11-25 |
| Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies Rapamycin, High dose etoposide and cytarabine (HiVAC) - ALL, Burkitt's Lymphoma | Phase 1 / Phase 2 | Terminated | Abramson Cancer Center at Penn Medicine | 4 | 2007-01-01 | 2025-11-05 |
Leukemia, Myeloid, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Refractory, with Excess of Blasts (1) · Burkitt Lymphoma (1) · Hematologic Diseases (1) · Hodgkin Disease (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1)
Hemic and Lymphatic Diseases (4) · Hematologic Diseases (3) · Leukemia (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia, Lymphoid (2) · Leukemia, Myeloid (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2) · Anemia (1) · Anemia, Refractory (1) · Bone Marrow Diseases (1)
Cytarabine (1) · Etoposide (1) · Sirolimus (1)
AO GENERIUM (1) · Abramson Cancer Center at Penn Medicine (1) · Duke University (1) · OncoTherapy Science, Inc. (1) · Roncarolo, Maria Grazia, MD (1)
United States (3) · Russia (1)
Mitchell Horwitz, MD (1) · Oksana A. Markova, MD (1) · Olatoyosi Odenike, MBBS (1) · Rajni Agarwal, MD (1) · Selina Luger, MD (1)
P01CA049605 (1)